Vaccines under test and an economic dispute
30
Nov
Even recognizing flaws in the theses, Pfizer’s vaccines against 
covid-19 should be approved within a few days, the Financial Times reported on Sunday, so the United Kingdom becomes the first country in the west to have a vaccine, and vaccination can begin. on December 7, in Brazil, the race is for Coronavac, no matter which one is safer, behind the vaccines there are economic deals and investments made in the manner of betting and not really scientific criteria.
In Brazil the authorization is made by Anvisa, in Europe by the European Medicines Agency and the departure of the United Kingdom from the European Union, a final Brexit transition is for December 31, but the Regulatory Agency for Medicines and Health Products in the United Kingdom has the power to temporarily authorize the products, and there is an obvious interest in the UK even though it is in partnership with German BioNTech.
The process could be applied to the vaccine developed by AstraZeneca and the University of Oxford (Brazil participates in FioCruz), on Sunday, Friday (27) the government asked the regulator to review the AstraZeneca-Oxford vaccine, thus showing the real interest .
Current data on the efficiency of Coronavac, a medical vaccine by the Chinese company Sinovac and which has a partnership with the Butantan Institute, should be announced in early December, and an approval in record time would be for January, however the effectiveness is different from the tests that verify side effects, contraindications and long-term efficiency, also a Pfizer was questioned recently due to the tests.
The long-term effects studies indicated that perhaps a single vaccine would not solve the pandemic problem, an article was published in October in The Lancet Infectious Diseases, which lit up a warning sign about vaccines, and said that he did not know until that time. data if vaccines were candidates were effective in severe forms of the disease, the warning sign remains on.
